Last Price$1.48Cboe Real-Time Last Sale as of 10:35AM ET 6/30/22
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change+0.005(0.34%)
Bid (Size)$1.47 (11,794)
Ask (Size)$1.48 (41,300)
Day Low / High$1.47 - 1.48
Volume1.7 M

View Biotechnology IndustryPeer Comparison as of 06/30/2022


Epizyme Inc ( NASDAQ )

Price: $1.48
Change: +0.005 (0.34%)
Volume: 1.7 M
10:35AM ET 6/30/2022

Alpine Immune Sciences Inc ( NASDAQ )

Price: $8.00
Change: -0.12 (1.48%)
Volume: 2.3 K
10:29AM ET 6/30/2022

Cymabay Therapeutics Inc ( NASDAQ )

Price: $2.80
Change: -0.05 (1.75%)
Volume: 62.2 K
10:28AM ET 6/30/2022

Outlook Therapeutics Inc ( NASDAQ )

Price: $1.02
Change: -0.02 (1.92%)
Volume: 14.6 K
10:34AM ET 6/30/2022

Aldeyra Therapeutics Inc ( NASDAQ )

Price: $3.92
Change: -0.02 (0.38%)
Volume: 83.8 K
10:35AM ET 6/30/2022

Read more news Recent News

--Cowen Downgrades Epizyme to Market Perform From Outperform; Price Target is $1.50
5:12AM ET 6/28/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Sector Update: Health Care Stocks Mixed Pre-Bell Monday
9:25AM ET 6/27/2022 MT Newswires

Health care stocks were mixed pre-bell Monday. The Health Care SPDR (XLV) was up 0.12%, and the iShares NASDAQ Biotechnology Index (IBB) was recently 0.20%...

Wall Street Set for Positive Open, Extending Gains on Easing Inflation Expectations
9:20AM ET 6/27/2022 MT Newswires

US stocks were set for narrow gains Monday, extending previous session's gains after an inflation expectation gauge showed a slight easing. Dow Jones...

Wedbush Cuts Epizyme to Neutral From Outperform, Price Target to $1.45 From $7, Citing Ipsen Offer
8:23AM ET 6/27/2022 MT Newswires

Epizyme (EPZM) has an average rating of buy and price targets ranging from $0.60 to $8, according to analysts polled by Capital IQ. (MT Newswires covers...

Company Profile

Business DescriptionEpizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA. View company web site for more details
Address400 Technology Square
Cambridge, Massachusetts 02139
Number of Employees124
Recent SEC Filing06/28/2022SC 13D/A
President, Chief Executive Officer, CFO & DirectorGrant C. Bogle
Chief Operating OfficerJerald Korn
Chief Scientific Officer & Executive VPJeffery L. Kutok
Secretary, Senior Vice President & General CounselJohn F. Weidenbruch

Company Highlights

Price Open$1.46
Previous Close$1.47
52 Week Range$0.41 - 8.59
Market Capitalization$243.2 M
Shares Outstanding164.9 M
SectorHealth Technology
Next Earnings Announcement08/08/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$2.20
Beta vs. S&P 500N/A
Revenue$21.7 M
Net Profit Margin-614.08%
Return on Equity-1,287.29%

Analyst Ratings as of 06/27/2022

Consensus RecommendationConsensus Icon
Powered by Factset